SEC Form 4 · accession 0001093557-19-000078
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew K Balo
Officer — *
Period of report
Mar 12, 2019
Accepted (ET)
Mar 13, 2019 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 12, 2019 | S | 2,222 | $142.7922 | D | 85,912 | D | |
| Common StockF1,F2 | Mar 12, 2019 | S | 6,399 | $142.7922 | D | 79,513 | D | |
| Common StockF1,F2 | Mar 12, 2019 | S | 2,296 | $142.7922 | D | 77,217 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2Included in this number are 50,242 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,587 of which were granted on March 8, 2017 and shall vest through March 8, 2020.
Remarks
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development